Clinical trial · Interventional
Evaluation of PET-CT Scanner Performances to Detect Infra-centimetric Lesions in Patients With Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective, monocentric study aiming to evaluate the PET-CT (Positron Emission Tomography - Computed Tomography) scanner performances to detect infra-centimetric lesions in two groups of patients with cancer and of different BMI (Body Mass Index) classes (BMI ≤ 25 and BMI \> 25). For each patient, two consecutive PET-CT scanner will be performed using the "Discovery MI" and "Discovery IQ" PET-CT scanner systems. Virtual lesions will then be created on images obtained. Images will be interpreted by two independent observers. The study participation of each patient will be a maximum of 24 hours.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patients with a cancer for which a FDG-PET scanner must be performed | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Patients with a cancer
- interventionNames
- Other: Patients with a cancer for which a FDG-PET scanner must be performed
Primary outcomes (1)
- measure
- Relative rate of virtual lesions detected by each system ("Discovery MI" and "Discovery IQ")
- timeFrame
- 24 hours for each patient
Secondary outcomes (1)
- measure
- Rate of Inter-observer concordance in radiological images interpretation
- timeFrame
- 24 hours for each patient
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years old. 2. A patient with a cancer for which a FDG-PET (fluorodeoxyglucose-positron emission tomography) must be performed according to the standard practices 3. OMS ≤ 1, Karnofsky Index \> 70. 4. Negative pregnancy test at inclusion. 5. Patient able to maintain a lying position in a strict supine position twice. 6. Patient affiliated to a Social Health Insurance in France. 7. Patient who has signed informed consent prior inclusion in the study and before any specific procedures for the study. Exclusion Criteria: 1. Patient with unbalanced diabetic 2. Patient with a formal contraindication usual for certain imaging procedures (severe claustrophobia, wearing a heart valve, pacemaker, etc.) 3. Pregnant or breastfeeding woman 4. Any psychological, family, geographical or sociological condition that does not allow medical follow-up and/or procedures provided for in the study protocol to be respected 5. Patient protected by law
References
Publications (1)
- RESULTMaronnier Q, Robaine N, Chaltiel L, Dierickx LO, Cassou-Mounat T, Terroir M, Vija L, Vallot D, Brillouet S, Lamesa C, Filleron T, Caselles O, Courbon F. Insertion of synthetic lesions on patient data: a method for evaluating clinical performance differences between PET systems. EJNMMI Phys. 2024 Jan 22;11(1):9. doi: 10.1186/s40658-023-00610-2. PMID 38252388